Phase 1/2 × Has results × Lymphoma × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
58 enrolled 11 charts
NCT00788125 2023-07-14

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

City of Hope Medical Center

Phase 1/2 Terminated
7 enrolled 9 charts
NCT00416351 2022-05-17

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
29 enrolled 15 charts